AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7920946
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol valerate (E2-V) 4 mg/day for 28 days
Trial: 1095132
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dummy tablets)
Trial: 20177421
Drug: p38 kinase
RxNorm normalized name: Kinase (enzyme-activating), uro-urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p38 kinase inhibitor
Trial: 20177421
Drug: Specific enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific enzyme inhibitors and expressed recombinant enzymes
Trial: 19705093
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (training program with simple gymnastic and physiotherapeutic exercises)
Trial: 10699342
Drug: Vaccine containing
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine containing recombinant MSP2 (3D7 allele), MSP1 (190LCS.T3), and RESA antigen (C terminal 771 amino acids) in Montanide ISA 720 adjuvant, administered in two doses 6 weeks apart.
Trial: 10699342
Drug: Placebo (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (adjuvant emulsion), administered in two doses 6 weeks apart.
Trial: 10699342
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (vaccine and placebo) were challenged with approximately 140 ring infected red cells of the 3D7 cloned line, 4 weeks after the second dose.
Trial: 10699342
Drug: Vaccine and
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine and placebo groups.
Trial: 9471828
Drug: Low power
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low power laser therapy (904 nm, 5 kHz, in the dose of 1 J/cm2)
Trial: 9471828
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of corticosteroid infiltration and laser therapy
Trial: 9471828
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Low power laser therapy)
Trial: 8398330
Drug: Mitomycin-C (MMC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (MMC), 20 mg/m2 intravenously one day every 6 weeks for four courses, starting before the sixth week after surgery
Trial: 8398330
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no further treatment after surgery
Trial: 8398330
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (MMC) treatment
Trial: 27568492
Drug: Percutaneous ilioinguinal
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous ilioinguinal nerve block with additional perineural infiltration of the ilioinguinal, iliohypogastric, genitofemoral nerves (total of 12 mL of 0.5% bupivacaine)
Trial: 16105975
Drug: Continued conventional
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued conventional chemotherapy
Trial: 12269674
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Iron plus folate) in the subgroup with lowest quartile of baseline haemoglobin values
Trial: 7814158
Drug: Captopril (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25 mg orally 15 min before thrombolysis) + Metoprolol (i.v. not later than 1 h, then orally)
Trial: 7814158
Drug: Captopril (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25 mg orally 15 min before thrombolysis)
Trial: 2773841
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran injection at 2 months
Trial: 2019922
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran injection
Trial: 319140
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline (0.01 mg/kg, maximum 0.25 mg)
Trial: 319140
Drug: Subcutaneous epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous epinephrine (0.01 mg/kg, maximum 0.25 mg)
Trial: 10642384
Drug: MCT+CHO (0.36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT+CHO (0.36 g tricaprin (C10:0)/kg plus 0.72 g sucrose/kg)
Trial: 10642384
Drug: CHO (0.72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (0.72 g sucrose/kg)
Trial: 8851458
Drug: Oxaprozin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaprozin (1200 mg/d)
Trial: 8851458
Drug: Nabumetone (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (1500 mg/d)
Trial: 1510191
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (50% oxygen inhalation)
Trial: 6486489
Drug: Aminophylline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (2 mg/kg intravenously) after diazepam (15 mg intravenously)
Trial: 6486489
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after diazepam (15 mg intravenously)
Trial: 24107737
Drug: LCI699 (aldosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 (aldosterone synthase inhibitor)
Trial: 12134255
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (ZDV, 3TC, APV)
Trial: 23246635
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg IV buprenorphine
Trial: 23246635
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg IV buprenorphine
Trial: 23246635
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg IV buprenorphine
Trial: 15327190
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (F and A)
Trial: 11269574
Drug: BAY 12‐9566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 12‐9566 400 mg
Trial: 9552067
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron 2 mg
Trial: 15139789
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron 32 mg
Trial: 20837354
Drug: EGb 761®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761® (240 mg once daily)
Trial: 8446850
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg single dose)
Trial: 3528403
Drug: MCBP (melphalan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCBP (melphalan, cyclophosphamide, and carmustine in combination)
Trial: 3528403
Drug: Seq‐MCBP (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seq‐MCBP (sequential MCBP)
Trial: 3065083
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at a rate of 20 mg kg‐1 h‐1 for 5 min, reducing to 12 mg kg‐1 h‐1 for 10 min and then 6 mg kg‐1 h‐1 thereafter.
Trial: 15225149
Drug: Topiramate treatment
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate treatment (adjunctive)
Trial: 7684551
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (0.09U (kg BW)‐1 day‐1 sc)
Trial: 3101524
Drug: Ibuprofen at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen at a dose of 2,400 mg per day
Trial: 11022811
Drug: Psychosocial treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial treatments for cocaine dependence
Trial: 27091970
Drug: Psilocybin (Psi)
RxNorm normalized name: psi-Norephedrine
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (Psi) 0.215 mg/kg
Trial: 15049436
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol plus levonorgestrel (0.02 mg/0.1 mg)
Trial: 2691100
Drug: High-dose steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroids (125 mg methylprednisolone I.M. the night before and morning of PTCA, and prednisone 60 mg p.o. Q.D. for 1 week post-PTCA)
Trial: 7013060
Drug: No steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroids (control group)
Trial: 24025700
Drug: High-dose steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroids
Trial: 16302558
Drug: Metronidazole 0.75%
RxNorm normalized name: METRONIDAZOLE 0.75% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.75% gel
Trial: 16316969
Drug: IV amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV amiodarone (low dose)
Trial: 16316969
Drug: IV amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV amiodarone (medium dose)
Trial: 16316969
Drug: IV amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV amiodarone (all doses)
Trial: 1914758
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose antacid (magaldrate) 88 mmol/day, given in three divided doses (10 ml after breakfast and lunch, 20 ml at bedtime) for eight weeks
Trial: 1914758
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg/day, given in two divided doses (400 mg after breakfast and 400 mg at bedtime) for eight weeks
Trial: 1914758
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose antacid (magaldrate) 88 mmol/day, given in two schedules for four weeks
Trial: 1914758
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg/day, given in two divided doses for four weeks
Trial: 6136936
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg temazepam
Trial: 1967533
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg temazepam
Trial: 21751435
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of ropivacaine 0.5%
Trial: 15814754
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of ropivacaine 0.5%
Trial: 16707408
Drug: Montelukast 4-mg
RxNorm normalized name: montelukast 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 4-mg oral granules
Trial: 15504180
Drug: Methylprednisolone 125
RxNorm normalized name: methylprednisolone 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 125 mg i.v.
Trial: 15504180
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg i.v. (active control)
Trial: 9261520
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m2 (30 min IV infusion on days 1, 8, 15 of a 28-day cycle)
Trial: 9587343
Drug: Full-dose Klean
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose Klean Prep
Trial: 9587343
Drug: Half-dose Klean
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose Klean Prep
Trial: 14482
Drug: oxazepam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxazepam (3 X 15 mg per day)
Trial: 14482
Drug: oxypertine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxypertine (3 X 10 mg per day)
Trial: 31934995
Drug: sampeginterferon beta
RxNorm normalized name: sampeginterferon beta-1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sampeginterferon beta 1a 180 μg
Trial: 31934995
Drug: sampeginterferon beta
RxNorm normalized name: sampeginterferon beta-1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sampeginterferon beta 1a 240 μg
Trial: 31934995
Drug: low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose interferon beta‐1a (LIB) 30 μg
Trial: 22082677
Drug: Prophylactic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic heparin anticoagulation
Trial: 27296126
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (AP)
Trial: 29563781
Drug: Roflumilast 250
RxNorm normalized name: ROFLUMILAST 250MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 250 µg once daily (OD) followed by 500 µg OD for 8 weeks
Trial: 29563781
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 µg every other day (EOD) followed by 500 µg OD for 8 weeks
Trial: 29563781
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 µg once daily (OD) for 8 weeks
Trial: 25595565
Drug: Allopurinol 100
RxNorm normalized name: allopurinol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 100 mg/d
Trial: 24293994
Drug: Usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual therapy (Control)
Trial: 25400252
Drug: Allopurinol treatment
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol treatment
Trial: 8792761
Drug: Triiodothyronine augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine augmentation
Trial: 21209073
Drug: Intramyocardial bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial bone marrow cell injection
Trial: 17728426
Drug: Aripiprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15 mg/day for the first 4 weeks, then 30 mg/day for the following 4 weeks)
Trial: 2574766
Drug: Oxpentifylline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxpentifylline (500 mg over 4 h) after 100 ng endotoxin injection
Trial: 2574766
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 ng endotoxin injection without oxpentifylline)
Trial: 1183792
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Heparin (Liquemin Roche) subcutaneously, 5000 units 2 hours pre-operatively and every 12 hours until the eighth post-operative day
Trial: 1183792
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Heparin
Trial: 1183792
Drug: Oral anti-coagulants
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-coagulants (Sintrom)
Trial: 26156625
Drug: Rosuvastatin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (2.5 mg)
Trial: 26156625
Drug: Pitavastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (1 or 2 mg)
Trial: 21971374
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg
Trial: 18452434
Drug: Cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing retinol, lactose and glycolic acid applied twice daily for 12 weeks
Trial: 18452434
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied twice daily for 12 weeks
Trial: 16670692
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets twice daily for 6 months)
Trial: 11680668
Drug: Control (Heparin)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (Heparin)
Trial: 7964961
Drug: Conventional-dose alizapride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose alizapride (day 1, 100 mg i.v. and 4 x 50 mg orally; days 2 through 6, 4 x 50 mg orally)
Trial: 7964961
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the dose of tropisetron (10 mg once daily)
Trial: 23294549
Drug: DMPA-SC self-administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMPA-SC self-administration
Trial: 23294549
Drug: DMPA-SC self-administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMPA-SC self-administration proficiency ratings
Trial: 18327010
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg IM weekly for 12 weeks (group 2)
Trial: 1735484
Drug: Parlodel (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parlodel (5 mg/d for first 15 days, then 10 mg/d for 1 month)
Trial: 6371278
Drug: Dihydroergotamine mesylate,
RxNorm normalized name: Dihydroergotamine Mesylate, 4 mg/mL nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 5,000 IU
Trial: 6371278
Drug: Dihydroergotamine mesylate,
RxNorm normalized name: Dihydroergotamine Mesylate, 4 mg/mL nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 2,500 IU
Trial: 6371278
Drug: Heparin sodium,
RxNorm normalized name: heparin sodium, bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin sodium, 5,000 IU alone
Trial: 31206083
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of zinc sulfate daily for 14 days
Trial: 25007690
Drug: Epidural butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural butorphanol 0.04 mg/kg
Trial: 25007690
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 0.06 mg/kg
Trial: 22748873
Drug: Degarelix 240
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg
Trial: 20131032
Drug: Qianggan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianggan Capsule (QGC)
Trial: 20131032
Drug: Polyene phosphatidylcholine
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyene phosphatidylcholine capsule (PPC)
Trial: 17418289
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration (in the emergency room)
Trial: 16271912
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg daily (n = 120)
Trial: 16271912
Drug: Naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 750 mg daily and Lansoprazole 30 mg daily (n = 122)
Trial: 7752918
Drug: Doxazosin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (maximum 12 mg/d)
Trial: 2182169
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral pulse methotrexate
Trial: 22300739
Drug: Ergocalciferol 50,000
RxNorm normalized name: ergocalciferol 50,000 intl units oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol 50,000 IU weekly
Trial: 12404693
Drug: Nicotine (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (21 mg/day via transdermal patch)
Trial: 9109740
Drug: Placebo (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (transdermal patch)
Trial: 8674919
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with porfimer sodium and argon‐pumped dye laser
Trial: 31838924
Drug: PRGF injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRGF injection once
Trial: 6242074
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin
Trial: 10573550
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A, 15 mg retinol equivalent (RE) with TOPV
Trial: 10573550
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A, 7.5 mg RE with TOPV
Trial: 1672698
Drug: Atenolol (ATN)
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol (ATN) 100 mg
Trial: 7154707
Drug: Weekly bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly bolus (5 mg/m2 i.v. X 4)